Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Roche	Terminated	Ocrelizumab	3b	MN39159	KFSH&RC-R
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Biogen	Ongoing	Interferon beta-1a	3	105MS306	KFSH&RC-J
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Biogen	Ongoing	Interferon beta-1a	3	105MS306	KFSH&RC-J
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Bristol-Myers Squibb	Terminated	NIVOLUMAB IPILIMUMAB	3	CA209-227	KFSH & RC-R
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients	Alcon	Completed	Travoprost 0.004%	1	C-12-009	KKESH
"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). "	Alexion	Completed	Asfotase Alfa	2	ENB-010-10	KFSH & RC-R
An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors.	Novartis	Completed	Everolimus	3b	CRAD001K24133	KFSH & RC-R
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)	AbbVie	Ongoing	ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV)	3b	M14-423	KKUH
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)	Albireo	Ongoing	A4250	3	A4250-008	KFSH&RC-R
"An open-label extension study of the long-term safety, tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)."	GSK	Completed	Ambrisentan	3	116457	KFMC